Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure Mikhail Kosiborod, Ingrid Gause-Nilsson, John Xu,

Slides:

Advertisements

Similar presentations

Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP 

Advertisements

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according.

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Outcomes Associated With Microalbuminuria: Effect.

Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with.

Poor glycemic control and decreased renal function are associated with increased intrarenal RAS activity in Type 2 diabetes mellitus S. Nakatani, E.

Influence of Diabetes on Cardiac Resynchronization Therapy With or Without Defibrillator in Patients With Advanced Heart Failure Jalal k. Ghali, MD,

Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study Denise S. Costa, Flavia L.

Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes Bernt Johan von Scholten, Tine.

Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies Richard.

Pre-gestational versus gestational diabetes: A population based study on clinical and demographic differences Alex Fong, Allison Serra, Tiffany Herrero,

Robert Vigersky, Maneesh Shrivastav

Continued Smoking Exacerbates but Cessation Ameliorates Progression of Early Type 2 Diabetic Nephropathy Kantima Phisitkul, MD, Khaled Hegazy, MD, Temduang.

Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment Ippei Kanazawa, Ken-ichiro Tanaka, Masakazu.

Neal B, et al. Diabetes Care 2015;38:403–411

Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline.

Associations of renal impairment (adjusted odds ratio and 95% CI) and the presence of individual small vessel disease markers stratified by age. Associations.

Early Evolution and Correlates of Urine Albumin Excretion in Patients Presenting With Acutely Decompensated Heart FailureClinical Perspective by Satoshi.

So What is Albuminuria? An elevated urinary albumin excretion is a marker of endothelial dysfunction that symbolizes the kidney’s way to translate the.

Volume 70, Issue 8, Pages (October 2006)

Shoshana H. Ballew, PhD, Yan Chen, BS, Natalie R. Daya, MPH, Job G

Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis Patricia M.

Treatment of low back pain exacerbations with willow bark extract: a randomized double-blind study Sigrun Chrubasik, MD, Elon Eisenberg, MD, Edith Balan,

M. Sriharibabu, K. Komali, T. Sivakumar, Bhimasen Soren

Volume 79, Issue 12, Pages (June 2011)

PDE5 inhibitor sildenafil in the treatment of heart failure: A meta-analysis of randomized controlled trials Xiao-Dong Zhuang, Ming Long, Fei Li, Xun.

Volume 93, Issue 1, Pages (January 2018)

Chronic Kidney Disease in Diabetes

Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD

M. Sriharibabu, K. Komali, T. Sivakumar, Bhimasen Soren

Volume 83, Issue 2, Pages (February 2013)

Advances in CKD Detection and Determination of Prognosis: Executive Summary of the National Kidney Foundation–Kidney Early Evaluation Program (KEEP) 2012.

Volume 81, Issue 7, Pages (April 2012)

Your Kidneys May Outlive You

The Natural Course of Microalbuminuria among African Americans with Type 2 Diabetes: A 3-Year Study Mohamed G. Atta, MD, MPH, Kesha Baptiste-Roberts,

Erratum American Journal of Kidney Diseases

Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis Xiaole Su, MD, Lu Zhang, MD, Jicheng Lv, MD, PhD, Jinwei Wang, PhD,

Molly E. Waring, PhD, Jane S

Glycemic Status and Mortality in Chronic Kidney Disease According to Transition Versus Nontransition to Dialysis Connie M. Rhee, MD, MSc, Csaba P. Kovesdy,

Volume 79, Issue 12, Pages (June 2011)

Volume 93, Issue 1, Pages (January 2018)

Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries British Journal of Anaesthesia

Volume 77, Issue 7, Pages (April 2010)

CKD in Aboriginal Australians

Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study G.

Different small-dose sufentanil blunting cardiovascular responses to laryngoscopy and intubation in children: a randomized, double-blind comparison†

Effect of Spironolactone on Physical Performance in Older People with Self-reported Physical Disability Louise A. Burton, MD, Deepa Sumukadas, MD, Miles.

Drug Dose Adjustments in Patients With Renal Impairment

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

The Lancet Diabetes & Endocrinology

Volume 73, Issue 8, Pages (April 2008)

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Volume 72, Issue 7, Pages (October 2007)

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Volume 75, Issue 1, Pages (January 2009)

Study protocol. Study protocol. Fourteen patients had research renal biopsies, and 17 patients with macroalbuminuria had renal biopsies for clinical reasons.

Mean mesangial area (micron2) across normal controls (normal C), patients with type 2 diabetes and normoalbuminuria (normo), patients with type 2 diabetes.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Volume 63, Pages S13-S16 (February 2003)

Shoshana H. Ballew, PhD, Yan Chen, BS, Natalie R. Daya, MPH, Job G

Atrasentan reduces albuminuria in diabetic apoE KO mice.

Friends, social networks, and progressive chronic kidney disease

Volume 73, Issue 11, Pages (June 2008)

(D) Systolic blood pressure (BP) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. . (D) Systolic blood pressure.

Pathway to initial antihypertensive therapy in patients with diabetes

International Journal of Cardiology

GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A:

HR for myocardial infarction.

Jacob J.E. Koopman, MD, PhD American Journal of Kidney Diseases

Presentation transcript:

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure Mikhail Kosiborod, Ingrid Gause-Nilsson, John Xu, Christian Sonesson, Eva Johnsson Journal of Diabetes and Its Complications Volume 31, Issue 7, Pages 1215-1221 (July 2017) DOI: 10.1016/j.jdiacomp.2017.02.001 Copyright © 2017 Elsevier Inc. Terms and Conditions

Fig. 1 Mean change from baseline in HbA1c, weight, and systolic blood pressure over time. *Pooled data from five studies ≤52weeks (NCT00663260, NCT00680745, NCT00673231, NCT01031680, NCT01042977); †Pooled data from two studies ≤52weeks (NCT01031680, NCT01042977). Data based on longitudinal repeated-measures models, excluding data after rescue therapy for inadequate glycemic control (HbA1c, weight) or change in medication affecting blood pressure (SBP). Adj, adjusted; BL, baseline; CI, confidence interval; DAPA, dapagliflozin; SBP, systolic blood pressure. Journal of Diabetes and Its Complications 2017 31, 1215-1221DOI: (10.1016/j.jdiacomp.2017.02.001) Copyright © 2017 Elsevier Inc. Terms and Conditions

Fig. 2 Mean change from baseline in estimated glomerular filtration rate over time. Pooled data from five studies ≤52weeks. N is the number of randomized patients who received ≥1 dose of study medication. Includes data after rescue therapy. BL, baseline; DAPA, dapagliflozin; SD, standard deviation. Journal of Diabetes and Its Complications 2017 31, 1215-1221DOI: (10.1016/j.jdiacomp.2017.02.001) Copyright © 2017 Elsevier Inc. Terms and Conditions

Fig. 3 Percentage of patients moving by ≥1 category between normoalbuminuria*, microalbuminuria†, and macroalbuminuria‡ from baseline to Week 24. Includes data after rescue therapy. Pooled data from five studies are based on a 24-week double-blind treatment period. *UACR of 0–<30mg/g; †UACR of 30–<300mg/g; ‡UACR ≥300mg/g. §Patients shifting from micro- to normoalbuminuria or from macro- to micro- or normoalbuminuria (DAPA, n=62; Placebo, n=51). #Patients shifting from normo- to microalbuminuria or from normo- or micro- to macroalbuminuria (DAPA, n=158; Placebo, n=143). DAPA, dapagliflozin; UACR, urine albumin-to-creatinine ratio. Journal of Diabetes and Its Complications 2017 31, 1215-1221DOI: (10.1016/j.jdiacomp.2017.02.001) Copyright © 2017 Elsevier Inc. Terms and Conditions